SCHEMBL16385161

SCHEMBL16385161

COc1ccc(-c2nccc(C)n2)cc1C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 1/20 0.52
PDGFRA P16234 1/20 0.52
MAPT P10636 5/20 0.49
KDM4E B2RXH2 2/20 0.49
S1PR1 P21453 4/20 0.46
S1PR3 Q99500 1/20 0.46
RAB9A P51151 4/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
NPC1 O15118 3/20 0.44
CYP1A1 P04798 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2E1 P05181 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C8 P10632 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2A6 P11509 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP4B1 P13584 1/20 0.41
CYP2B6 P20813 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15345125 0.90 S1PR1 (0.48) PDGFRBPDGFRAMAPTKDM4ES1PR1
SCHEMBL16385152 0.83 PDGFRB (0.54) PDGFRBPDGFRAMAPTKDM4ERAB9A
SCHEMBL16385412 0.82 PDGFRB (0.48) PDGFRBPDGFRAMAPTKDM4ES1PR1
SCHEMBL22130305 0.81 ALDH1A1 (0.56) MAPTKDM4ES1PR1S1PR3MEN1
SCHEMBL16385404 0.81 CTSS (0.48) MAPTKDM4ES1PR1S1PR3LMNA
SCHEMBL5679981 0.79 CYP1A1 (0.46) MAPTKDM4ENPC1CYP1A1CYP1A2
SCHEMBL2666284 0.77 MEN1 (0.40) RAB9AMEN1KMT2ANPC1CYP1A2
SCHEMBL16385240 0.77 TLR8 (0.47) S1PR1MEN1KMT2A
SCHEMBL2666274 0.76 CLK4 (0.63) MAPTKDM4ERAB9AMEN1KMT2A
SCHEMBL31186653 0.74 CYP1A1 (0.46) MEN1KMT2ACYP1A1CYP1A2CYP2E1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3020715-B1 TETRAZOLINONE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL CO (JP) 2021-06-16 EP disclosed
US-9888688-B2 Tetrazolinone compounds and applications thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2018-02-13 US disclosed
US-9888688-B2 Tetrazolinone compounds and applications thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2018-02-13 US disclosed
US-20160150787-A1 TETRAZOLINONE COMPOUNDS AND APPLICATIONS THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2016-06-02 US disclosed
US-20160150787-A1 TETRAZOLINONE COMPOUNDS AND APPLICATIONS THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2016-06-02 US disclosed
WO-2015005499-A1 TETRAZOLINONE COMPOUND AND USE THEREOF 住友化学株式会社 (JP) 2015-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160150787-A1 TETRAZOLINONE COMPOUNDS AND APPLICATIONS THEREOF SOD1, UQCRB, MT-CO1 PDGFRB 3608/4885PDGFRA 3060/4885MAPT 3902/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.